AVI Clinical Trial Update
Parent Project Muscular Dystrophy presents an AVI webinar on Wednesday, March 21 at 1pm eastern. The webinar will cover a pre-data update on AVI BioPharma's Phase IIb study evaluating eteplirsen for the treatment of Duchenne patients with mutations amenable to exon-51 skipping, and will be lead by Chris Garabedian, the CEO of AVI BioPharma.
If you are unable to attend this webinar, a link will be provided and posted on our website afterwards that will allow you to download the entire presentation.
Read more PPMD Blogs